ClinicalTrials.gg

Program

AZD4248

A development code.

Its studies are mostly in Renal Insufficiency, Chronic, led by AstraZeneca.

Furthest: phase 1, since Jun 9, 20251 company-led study, 1 open or runningNext primary completion: Jan 29, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Jun 9, 2025Jun 9, 2025Jan 29, 2027phase 1 · NCT07024823
  • Named in AstraZeneca’s own pipeline as AZD4248, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2025First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT07024823 · 192 planned · United States

Ahead

  1. Jan 29, 2027Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07024823

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07024823Renal Insufficiency, Chronic · United States1RecruitingJan 29, 2027192

How it is read

Names in the registry

  • “AZD4248”, 2 entries

Codes read as this program: AZD4248.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.